<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881217</url>
  </required_header>
  <id_info>
    <org_study_id>16182</org_study_id>
    <nct_id>NCT01881217</nct_id>
  </id_info>
  <brief_title>First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors</brief_title>
  <official_title>An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety,
      tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of
      BAY1179470 in subjects with advanced, refractory solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY1179470</measure>
    <time_frame>Cycle 1 and 2: pre-dose, 0.5, 1 , 2, 3, 5, 8, 24, 48, 72, 168 and 336 hours after start of the infusion, Cycle 3 and 4: pre-dose and 1 hour after start of the infusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) and minimal drug concentration (Cmin) of BAY1179470 in plasma after single and multiple dose administration</measure>
    <time_frame>Cycle 1 and 2: pre-dose, 0.5, 1 , 2, 3, 5, 8, 24, 48, 72, 168 and 336 hours after start of the infusion, Cycle 3 and 4: pre-dose and 1 hour after start of the infusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor response will be evaluated based on the RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (plasma)</measure>
    <time_frame>Cycle 1: pre-dose, 24 hours after start of the infusion and Day 15, Cycle 2, 3 and 4: pre-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (biopsy)</measure>
    <time_frame>Cycle 1: pre-dose and Day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Additional cohort only</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY1179470 (Dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1179470 (additional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1179470 (expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1179470</intervention_name>
    <description>BAY1179470 will be administered as a 1-hour intravenous infusion.</description>
    <arm_group_label>BAY1179470 (Dose escalation)</arm_group_label>
    <arm_group_label>BAY1179470 (additional)</arm_group_label>
    <arm_group_label>BAY1179470 (expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with advanced, histologically or cytologically confirmed solid tumors
             refractory to any standard therapy or have no standard therapy available or subjects
             actively refuse any treatment which would be regarded standard

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 and a
             life expectancy of at least 3 months

          -  At least moderate FGFR2 expression in the tumor tissue from archival samples is
             confirmed: for subjects in additional cohort

        Exclusion Criteria:

          -  History of severe allergic reactions to monoclonal antibody therapy

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg and/or
             diastolic blood pressure &gt; 90 mmHg, despite optimal medical management

          -  Any condition that is unstable or could jeopardize the safety of the subject and his
             / her compliance in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-Adachigun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Advanced, refractory solid tumors</keyword>
  <keyword>FGFR2</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
